Lambert-Eaton myasthenic syndrome.

  title={Lambert-Eaton myasthenic syndrome.},
  author={Michael C Mareska and Laurie Gutmann},
  journal={Seminars in neurology},
  volume={24 2},
Lambert-Eaton myasthenic syndrome (LEMS) is an idiopathic or paraneoplastic syndrome producing antibodies against presynaptic voltage-gated P/Q calcium channels. This decreases calcium entry into the presynaptic terminal, which prevents binding of vesicles to the presynaptic membrane and acetylcholine release. LEMS is most often associated with small cell lung cancer, although idiopathic presentations comprise approximately 40% of the cases. The most common initial complaint is proximal muscle… 

Figures and Tables from this paper

Síndrome miasteniforme de Lambert-Eaton idiopático

A 40 years old man with a four years history of proximal weakness, absent tendon reflexes and dry mouth is reported, showing a low-amplitude muscle response that increased dramatically after activation and the search for malignant tumors was negative.

IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status

  • I. Illa
  • Medicine, Biology
    Journal of Neurology
  • 2005
Controlled trials indicate that in MG, LEMS, and DM, IVIg at a total dose of 2 g/kg is a highly useful therapy, and further clinical investigation is required.

Neuromuscular paraneoplastic syndromes: the Lambert-Eaton myasthenic syndrome.

  • E. Prommer
  • Medicine, Psychology
    Journal of palliative medicine
  • 2010
A case of the Lambert-Eaton myasthenic syndrome diagnosed in a patient with small cell lung cancer presenting with profound weakness is described and the pathophysiology of the disorder, clinical characteristics and therapies used are described.

Empleo de la inmunoglobulina intravenosa en un caso atípico de síndrome de Lambert Eaton. Using Intravenous Inmunoglobulin in an Atypical Case of Lambert Eaton Síndrome.

In spite of suffering a Lambert Eaton myasthenic syndrome this patient presented an acute state making a crisis which was improved with the use of intravenous immunoglobulin, and the usage of this medication is considered as a therapeutic option in similar cases.

Autoantibodies in neuromuscular transmission disorders

  • A. Vincent
  • Medicine, Biology
    Annals of Indian Academy of Neurology
  • 2008
A brief review of the field of autoantibodies in myasthenia gravis and other neurotransmission disorders will illustrate how their study is helping to understand the etiology of rare but treatable neurological syndromes of the central nervous system.

Myopathy as paraneoplastic syndrome of colon malignancy in an elderly patient

A case with proximal muscular weakness as only symptom of colon cancer in the absence of other symptoms and laboratory abnormalities is reported, and the nosological classification as a possible atypical form of polymyositis is discussed.



Apheresis treatment in Lambert-Eaton myasthenic syndrome.

The Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of peripheral cholinergic transmission in which autoantibodies decrease the presynaptic release of acetylcholine at the neuromuscular junction and autonomic system and the indication of apheresis treatment of LEMS is discussed.

Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy.

Myasthenia gravis and Lambert-Eaton syndrome.

  • R. Pascuzzi
  • Medicine, Biology
    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis
  • 2002
Clinical manifestations, establishment of diagnosis, the natural history of myasthenia gravis, and therapeutic options are herein reviewed.

Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.

The high frequency of P/Q-type calcium-channel antibodies found in patients with Lambert-Eaton syndrome implies that antibodies of this specificity have a role in the presynaptic pathophysiology of this disorder.

Type 2 fiber predominance in lambert–eaton myasthenic syndrome

Serial muscle biopsies in a noncarcinomatous case of Lambert–Eaton myasthenic syndrome have shown progressive atrophy and loss of type 1 fibers, resulting in overwhelming type 2 predominance, which review of the literature suggests suggests has been observed in at least one other biopsied case.

Difference in distribution of muscle weakness between myasthenia gravis and the Lambert–Eaton myasthenic syndrome

In a patient suspected to have a myasthenic syndrome whose first symptom is ocular weakness, LEMS is virtually excluded andLimb weakness confined to the arms is only found in generalised myastshenia gravis and not in LEMS.

The immunopathogenesis of paraneoplastic neurological syndromes.

Current concepts in the immunopathogenesis of paraneoplastic neurological syndromes are examined, which suggest that aberrant expression of neuronal antigens can be detected in many tumours that are not complicated by non-metastatic neurological syndrome.

AAEE minimonograph #33: Electrodiagnostic approach to defects of neuromuscular transmission

  • J. Keesey
  • Medicine, Psychology
    Muscle & nerve
  • 1989
Electrical findings in myasthenia gravis, Lambert–Eatonmyasthenic syndrome, and botulinum intoxication are discussed from the subcellular level via the cellular level (SFEMG) to the integrated responses of whole muscle (RNS) as a rational means of understanding the technique of clinical repetitive nerve stimulation.

Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors.

Cases of a new myasthenic syndrome associated with intrathoracic neoplasms are described to show the use of electromyography and nerve stimulation in distinguishing the syndrome frommyasthenia gravis.

Heterogeneity of calcium channel autoantibodies detected using a small‐cell lung cancer line derived from a Lambert‐Eaton myasthenic syndrome patient

Different effects on Ca2+ flux inhibition by LEMS IgGs on the one hand and by L- and N-type channel antagonists on the other suggest that in many LEMS patients the autoantibodies target other VGCC subtypes besides L- or N-types, and that these are important in inducing the myasthenic disorder.